Abstracts tagged "Takayasu.s arteritis"

Abstract Number: PP03 • ACR Convergence 2025
My Journey of Risk, Loss, and Hope: The Role of Multidisciplinary Collaboration in Managing Pregnancy with Takayasu Arteritis
Tugce Turten Kaymaz
Background/Purpose: At the age of 26, the same month I got married, I was diagnosed with Takayasu Arteritis following severe chest and back pain. Hypertension…
Abstract Number: 2126 • ACR Convergence 2025
Preliminary Results of a Large, Global Registry Characterizing Childhood-Onset Takayasu Arteritis
Muserref Kasap Cuceoglu¹, James Bistolarides², Mario Sestan³, Samuel Gagne⁴, Nick McPhate⁵, Kimberly Morishita⁶, Vidya Sivaraman⁷, Linda Wagner-Weiner⁸, Seza Özen⁹, Marija Jelusic¹⁰ and David Cabral¹¹, ¹Hacettepe University, Ankara, Turkey, ²Medical College of Wisconsin, Wauwatosa, WI, ³University of Zagreb School of Medicine, Zagreb, Croatia, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵BC Children's Hospital, Vancouver, Canada, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁸University of Chicago, Chicago, IL, ⁹Hacettepe University Medical Faculty, Ankara, Turkey, ¹⁰University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ¹¹BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The rarity of childhood-onset Takayasu arteritis (c-TAK) has resulted in small cohorts for study that has limited the potential for evaluating its course and…
Abstract Number: 1632 • ACR Convergence 2025
PET/CT-Based Distribution of Arterial Involvement and Its Association With Clinical Outcomes in Takayasu Arteritis
Tokio Katakura¹, Tsuyoshi Shirai², Kentaro Mori¹, Mikihiro Takahashi¹, Yuito Tanno³, Soshi Okazaki³, So Itoi³, Yosuke Hoshi³, Tomoaki Machiyama³, Yusho Ishii³, Hiroko Sato³ and Hiroshi Fujii³, ¹Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, ²Department of Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan, ³Department of Rheumatology, Tohoku University Hospital, Sendai

Background/Purpose: PET/CT enables assessment of active vascular inflammation in Takayasu arteritis (TAK), which is often difficult to evaluate with conventional imaging. Although the distribution of…
Abstract Number: 1630 • ACR Convergence 2025
Validation of the classification algorithm using the modified 2022 ACR/EULAR giant cell arteritis classification criteria and Japanese Takayasu arteritis diagnostic criteria
Takahiko Sugihara¹, Masayoshi Harigai², Haruhito Uchida³, Yasuhiro Maejima⁴, Hajime Yoshifuji⁵, Yoshiko Watanabe⁶, Yasuhiro Onishi³, Shunsuke Furuta⁷, Tomonori Ishii⁸, Tsuyoshi Shirai⁹, Taio Naniwa¹⁰, Noriyoshi Ogawa¹¹, Yuko Kaneko¹², Hiroaki Dobashi¹³, Koichi Amano¹⁴, Jun Ishizaki¹⁵, Takako Miyamae¹⁶, Shuichi Ito¹⁷, Yoshinori Komagata¹⁸, Naoto Tamura¹⁹ and Yoshikazu Nakaoka²⁰, ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ²Department of Rheumatology, International University of Health and Welfare, Tokyo, Japan, ³Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan, ⁵Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁶Department of General Medicine, Kawasaki Medical School, Kurashiki,, Japan, ⁷Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁸Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁹Department of Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Nagoya City University Hospital, Nagoya, Japan, ¹¹Department of Internal Medicine ³, Hamamatsu University School of Medicine, Hamamatsu, Japan, ¹²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ¹⁴Department of rheumatology and clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, ¹⁵Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ¹⁶Department of Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University Hospital, Tokyo, Japan, ¹⁷Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan, ¹⁸Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ¹⁹Juntendo University School of Medicine, Tokyo, Japan, ²⁰Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute,, Suita, Japan
Background/Purpose: Given the increasing number of patients with giant cell arteritis (GCA) in Japan and the higher incidence of Takayasu arteritis (TAK) compared to Europe…
Abstract Number: 1631 • ACR Convergence 2025
New Arterial Damage in Takayasu’s Arteritis
Tanaz Kermani¹, Sema Kaymaz-Tahra², Aysegul Avcu³, Fatma Alibaz-Oner⁴, Haner Direskeneli³ and Peter Merkel⁵, ¹University of California Los Angeles, Santa Monica, CA, ²Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey, ³Marmara University, Istanbul, Turkey, ⁴MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DIVISION OF RHEUMATOLOGY, Istanbul, Turkey, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Damage is one of the consequences of disease and is often considered irreversible. This study aimed to evaluate new arterial damage in Takayasu’s arteritis…
Abstract Number: 1627 • ACR Convergence 2025
A systematic literature review to inform the 2025 EULAR recommendations for management of Polymyalgia Rheumatica and Large Vessel Vasculitis: management of disease including relapse and complications
Mrinalini Dey¹, Durga Prasanna Misra², Alice Bartoletti³, Georgina Ducker⁴, Sara Monti⁵, Bernhard Hellmich⁶, Chetan Mukhtyar⁷, Paul Studenic⁸ and Elena Nikiphorou⁹, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ³ASST Gaetano Pini CTO, Cremona, Italy, ⁴Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK, Norwich, England, United Kingdom, ⁵University of Pavia, Pavia, Pavia, Italy, ⁶Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ⁷Norfolk and Norwich University Hospital, Norwich, England, United Kingdom, ⁸Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁹King's College London, London, United Kingdom
Background/Purpose: EULAR recommendations informing the management of Polymyalgia Rheumatica (PMR) and Large Vessel Vasculitis (LVV) were previously published separately in 2015 [1] and 2020 [2]…
Abstract Number: 1622 • ACR Convergence 2025
Defective CD4+ regulatory T cells in active Takayasu arteritis patients can be improved by efficiency treatment of tofacitinib
jing luo¹ and Lan He², ¹the first affiliated hospital of xi'an jiaotong university, xi'an, China (People's Republic), ²The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China (People's Republic)
Background/Purpose: To investigate the efficacy of tofacitinib (TOF) in patients with active TAK, explore the effect on CD4+ regulatory T cells (Tregs) homeostasis and relationship…
Abstract Number: 1618 • ACR Convergence 2025
Use of JAK inhibitors in patients with refractory Takayasu arteritis: A worldwide retrospective study
Fatma Alibaz-Oner¹, İbrahim yahya Çakır², Alessandro Tomelleri³, Aysegul Avcu⁴, Kaitlin Quinn⁵, Durga Prasanna Misra⁶, Matthew Koster⁷, Peter Grayson⁸, Alojzija Hocevar⁹, Kenan Aksu¹⁰, Duygu Kerim¹¹, Ertugrul Cağrı Bolek¹², Elena Baldissera¹³, Corrado Campochiaro¹⁴, Lorenzo Dagna¹⁵, Sema Kaymaz-Tahra¹⁶ and Haner Direskeneli⁴, ¹MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DIVISION OF RHEUMATOLOGY, Istanbul, Turkey, ²Gazi University, Ankara, ³IRCCS San Raffaele Hospital, Milan, Italy, Milano, Italy, ⁴Marmara University, Istanbul, Turkey, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁶Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ⁷Mayo Clinic, Rochester, MN, ⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁹University Medical Center Ljubljana, LJUBLJANA, Slovenia, ¹⁰Ege Uni. Tip Fak., Istanbul, Turkey, ¹¹Ege University, Izmir, ¹²Gazi University, Rheumatology, Ankara, ¹³IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Milan, Italy, Milan, ¹⁴IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ¹⁵Ospedale San Raffaele, Milano, Italy, ¹⁶Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Glucocorticoids(GCs) are the mainstay of treatment in Takayasu arteritis (TAK). Conventional DMARDs(cDMARDs) and biologic DMARDS(bDMARDs) are often used as steroid sparing agents in TAK.…
Abstract Number: 1614 • ACR Convergence 2025
A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis
Alice Bartoletti¹, Georgina Ducker², Mrinalini Dey³, Durga Prasanna Misra⁴, Sara Monti⁵, Bernhard Hellmich⁶, Chetan Mukhtyar⁷, Paul Studenic⁸ and Elena Nikiphorou⁹, ¹Department of Rheumatology, ASST Gaetano Pini CTO, Milan, Italy, Milan, Lombardia, Italy, ²Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK, Norwich, England, United Kingdom, ³Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK, London, England, United Kingdom, ⁴Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ⁵University of Pavia, Pavia, Pavia, Italy, ⁶Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ⁷Norfolk and Norwich University Hospital, Norwich, England, United Kingdom, ⁸Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁹King's College London, London, United Kingdom
Background/Purpose: European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of Polymyalgia Rheumatica (PMR) and Large Vessel Vasculitis (LVV) date back to 2015…
Abstract Number: 0764 • ACR Convergence 2025
Frequency of large vessel vasculitis in giant cell arteritis with and without adventiitis of temporal artery – Is the presence of temporal arteritis sufficient to diagnose giant cell arteritis?-
Yoichiro Akiyama, Jun Nakamura, Ayako Kokuzawa, Hiroi Kusaka, Sho Tani, Fuminori Taniguchi, Kohei Morikawa, Haruka Kondo, Shotaro Yamamoto, Yasuyuki Kamata and Kojiro Sato, Jichi Medical University, Shimotsuke, Tochigi, Japan
Background/Purpose: Takayasu arteritis (TAK) and giant cell arteritis (GCA) belong to the large vessel vasculitis group. Differences between the two diseases have been reported based…
Abstract Number: 0756 • ACR Convergence 2025
Stroke Characteristics in Giant Cell Arteritis and Takayasu Arteritis: A Multicenter Cohort Study of 108 Patients
Omar Dhrif¹, Charlotte Caudron², Simon Parreau³, Eric Liozon³, Adrien Mirouse⁴, Jean-François Alexandra⁵, Laurent Sailler⁶, Mathieu Groh⁷, Hubert De Boysson⁸, Mikael Ebbo⁹, Cloé Comarmond¹⁰, Cécile Audrey Durel¹¹, Juliette Woessner¹², Pierre-André Jarrot¹³, Kévin Didier¹⁴, Goulabchand Radjiv¹⁵, Cacoub Patrice¹⁶, Bernard Bonnotte¹⁷, David Saadoun¹⁶ and Maxime Samson¹, ¹CHU Dijon Bourgogne, Dijon, France, ²CENTRE HOSPITALIER UNIVERSITAIRE DE DIJON, Paris, France, ³CHU de Limoges, Limoges, France, ⁴Médecine Interne et Immunologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, Paris, France, ⁵Internal Medicine, Hôpital Bichat, APHP, Paris, France, ⁶CHU Toulouse, Toulouse, France, ⁷Hôpital Foch, Suresnes, France, ⁸Internal Medicine, CHU Caean, Caen, France, ⁹Internal Medicine, Marseille-APHM, hôpital La Timone, Marseille, France, ¹⁰Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ¹¹Médecine Interne, Hôpital Saint Joseph Saint Luc, Lyon, Lyon, France, ¹²Médecine Interne, CH d’Avignon, Avignon, Avignon, France, ¹³Médecine Interne, Hôpital de la Conception, APHM, Marseille, Marseille, France, ¹⁴Médecine Interne, CHU Reims, Reims, Reims, France, ¹⁵Médecine Interne, CHU Nîmes, Nîmes, Nîmes, France, ¹⁶Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹⁷Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France
Background/Purpose: In giant cell arteritis (GCA) and Takayasu arteritis (TA), strokes occur in approximately 7.4% and 15.8% of cases, respectively. Although these two large-vessel vasculitides…
Abstract Number: 0747 • ACR Convergence 2025
Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis
Irene Carrión-Barberà¹, Ryan D. Stultz², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Kenneth Warrington¹², Peter Merkel⁷ and Christian Lood¹³, ¹Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ²University of Washington, Division of Rheumatology, Seattle, WA, ³University of South Florida, Tampa, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, ROCHESTER, MN, ¹³University of Washington, Division of Rheumatology, Seattle
Background/Purpose: Macrophages play a central role in the pathogenesis of large-vessel vasculitides, including giant cell arteritis (GCA) and Takayasu’s arteritis (TAK). Characterizing patterns of macrophage…
Abstract Number: 2180 • ACR Convergence 2024
The Association Between Age at Diagnosis and Patient-Reported Outcomes in Patients with Vasculitis
Jessica Bloom¹, Kaci Pickett-Nairne², Lori Silveira², David Cuthbertson³, Carol McAlear⁴, Peter Merkel⁴ and Karen James⁵, and the Vasculitis Clinical Research Consortium, ¹University of Colorado, Denver, CO, ²University of Colorado, Aurora, CO, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Utah, Salt Lake City, UT
Background/Purpose: Vasculitis is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether the degree of this impact varies based…
Abstract Number: 0522 • ACR Convergence 2024
Hematological Impact Assessment of Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis Treatment
Soo Min Ahn, Mi-Ra Cho, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo and Seokchan Hong, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Janus kinase (JAK) inhibitors' introduction has significantly revolutionized the therapeutic landscape, notably influencing the management strategies for rheumatoid arthritis (RA). To compare the effects…
Abstract Number: 2523 • ACR Convergence 2024
Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms
Sema Kaymaz-Tahra¹, Ozun Bayindir Tsechelidis², Burak Ince³, Ozlem Ozdemir-Isik⁴, Muhammet Emin Kutu⁵, Ozlem Karakas⁶, Tuba Demirci-Yildirim⁷, Zeliha Ademoglu⁸, Elif Ediboglu⁹, Burcu Ceren Uludogan¹⁰, Nazife Sule yaşar Bile¹⁰, Timucin Kasifoglu¹¹, Servet Akar¹², Hakan Emmungil⁸, Fatos Onen⁷, Ahmet Omma¹³, Nilüfer Alpay Kanıtez¹⁴, Ayten Yazici¹⁵, Ayse Cefle¹⁵, Murat Inanc³, Kenan Aksu¹⁶, Gokhan Keser¹⁷, Haner Direskeneli¹⁸ and Fatma Alibaz Öner¹⁸, ¹Bahcesehir University Faculty of Medicine, Istanbul, Turkey, ²Ottawa University, Ottawa, ON, Canada, ³Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Kocaeli University Faculty of Medicine, Kocaeli, Turkey, ⁵Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁶Ankara City Hospital, Ankara, Turkey, ⁷Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ⁸Trakya University, Edirne, Turkey, ⁹Mayo Clinic, Rochester, MN, ¹⁰Osmangazi University Faculty of Medicine, Rheumatology, Eskişehir, Turkey, Eskisehir, Turkey, ¹¹Osmangazi University Faculty of Medicine, Eskisehir, Turkey, ¹²Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ¹³Ankara Bilkent City Hospital, Ankara, Turkey, ¹⁴Koc University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey, ¹⁵Kocaeli University Faculty of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ¹⁶Ege University Faculty of Medicine, Izmir, Turkey, ¹⁷Ege University School of Medicine, Rheumatology, İzmir, Turkey, Izmir, Turkey, ¹⁸Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: There is no data on which patients biologic immunosuppressive (bIS) treatment should be chosen in Takayasu’s arteritis (TAK). In this study we aimed to…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].